AU2018276190B2 - 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases - Google Patents
5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases Download PDFInfo
- Publication number
- AU2018276190B2 AU2018276190B2 AU2018276190A AU2018276190A AU2018276190B2 AU 2018276190 B2 AU2018276190 B2 AU 2018276190B2 AU 2018276190 A AU2018276190 A AU 2018276190A AU 2018276190 A AU2018276190 A AU 2018276190A AU 2018276190 B2 AU2018276190 B2 AU 2018276190B2
- Authority
- AU
- Australia
- Prior art keywords
- pyridin
- pyrazolo
- fluoro
- phenyl
- carboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- QWDVPZXMURQVBV-UHFFFAOYSA-N CC(C)Cc1cc2c[n](-c(cc(cc3)NC(N(C4)CC4(F)F)=O)c3F)nc2nc1 Chemical compound CC(C)Cc1cc2c[n](-c(cc(cc3)NC(N(C4)CC4(F)F)=O)c3F)nc2nc1 QWDVPZXMURQVBV-UHFFFAOYSA-N 0.000 description 1
- ICCKXIXXJFVSSL-UHFFFAOYSA-N CC(C1)CN1C(Nc(cc1)cc(-[n]2nc3ncccc3c2)c1F)=O Chemical compound CC(C1)CN1C(Nc(cc1)cc(-[n]2nc3ncccc3c2)c1F)=O ICCKXIXXJFVSSL-UHFFFAOYSA-N 0.000 description 1
- KMYHFLOLPONRCR-UHFFFAOYSA-N CC(N(CC1)C1c1cc2c[n](-c(cc(cc3)NC(N(C4)CC4F)=O)c3F)nc2nc1)=O Chemical compound CC(N(CC1)C1c1cc2c[n](-c(cc(cc3)NC(N(C4)CC4F)=O)c3F)nc2nc1)=O KMYHFLOLPONRCR-UHFFFAOYSA-N 0.000 description 1
- 0 CC(NC(*)=O)=CC(OC)=O Chemical compound CC(NC(*)=O)=CC(OC)=O 0.000 description 1
- WFERYMPRVKKATO-UHFFFAOYSA-N CC1(CNC1)F Chemical compound CC1(CNC1)F WFERYMPRVKKATO-UHFFFAOYSA-N 0.000 description 1
- CEIWKYKASABBGE-UHFFFAOYSA-N CN(C)c1cc2c[n](-c(cc(cc3)N)c3F)nc2nc1 Chemical compound CN(C)c1cc2c[n](-c(cc(cc3)N)c3F)nc2nc1 CEIWKYKASABBGE-UHFFFAOYSA-N 0.000 description 1
- DWLZYSMBSVTUJR-UHFFFAOYSA-N Cc1c(-c2cc3c[n](-c(cc(cc4)NC(N5CCC5)=O)c4F)nc3nc2)nccc1 Chemical compound Cc1c(-c2cc3c[n](-c(cc(cc4)NC(N5CCC5)=O)c4F)nc3nc2)nccc1 DWLZYSMBSVTUJR-UHFFFAOYSA-N 0.000 description 1
- PWHDORBCUXTOQF-UHFFFAOYSA-N Cc1cc2c[n](-c(cc(cc3)NC(N4CCC4)=O)c3F)nc2nc1 Chemical compound Cc1cc2c[n](-c(cc(cc3)NC(N4CCC4)=O)c3F)nc2nc1 PWHDORBCUXTOQF-UHFFFAOYSA-N 0.000 description 1
- IVCVDBHSNOUXGK-UHFFFAOYSA-N Cc1cccnc1-c1cc2c[n](-c(cc(cc3)NC(N(C4)CC4F)=O)c3F)nc2nc1 Chemical compound Cc1cccnc1-c1cc2c[n](-c(cc(cc3)NC(N(C4)CC4F)=O)c3F)nc2nc1 IVCVDBHSNOUXGK-UHFFFAOYSA-N 0.000 description 1
- YXMQIZZNYHWUJM-UHFFFAOYSA-N Fc1cccnc1[BrH]I Chemical compound Fc1cccnc1[BrH]I YXMQIZZNYHWUJM-UHFFFAOYSA-N 0.000 description 1
- VHNYISHTVRZDFT-UHFFFAOYSA-N NNc1cc(NC(N2CCCC2)=O)ccc1F Chemical compound NNc1cc(NC(N2CCCC2)=O)ccc1F VHNYISHTVRZDFT-UHFFFAOYSA-N 0.000 description 1
- KHQOCDGXOFOVAR-UHFFFAOYSA-N O=C(Nc(cc1)cc(-[n]2nc3ncc(Br)cc3c2)c1F)N(C1)CC1(F)F Chemical compound O=C(Nc(cc1)cc(-[n]2nc3ncc(Br)cc3c2)c1F)N(C1)CC1(F)F KHQOCDGXOFOVAR-UHFFFAOYSA-N 0.000 description 1
- WNMQYDYBRWWEIK-UHFFFAOYSA-N O=C(Nc(cc1)cc(-[n]2nc3ncc(C4NCC4)cc3c2)c1F)N(C1)CC1F Chemical compound O=C(Nc(cc1)cc(-[n]2nc3ncc(C4NCC4)cc3c2)c1F)N(C1)CC1F WNMQYDYBRWWEIK-UHFFFAOYSA-N 0.000 description 1
- RDBDGZHWSDCSKJ-UHFFFAOYSA-N O=C(Nc(cc1)cc(-[n]2nc3ncc(CC(F)(F)F)cc3c2)c1F)N(C1)CC1F Chemical compound O=C(Nc(cc1)cc(-[n]2nc3ncc(CC(F)(F)F)cc3c2)c1F)N(C1)CC1F RDBDGZHWSDCSKJ-UHFFFAOYSA-N 0.000 description 1
- HKJYPKNEJSXVSH-UHFFFAOYSA-N O=C(Nc(cc1)cc(-[n]2nc3ncc(N4CCC4)cc3c2)c1F)N1CCC1 Chemical compound O=C(Nc(cc1)cc(-[n]2nc3ncc(N4CCC4)cc3c2)c1F)N1CCC1 HKJYPKNEJSXVSH-UHFFFAOYSA-N 0.000 description 1
- LIZNKHLUXKNNMO-UHFFFAOYSA-N O=C(Nc(cc1-[n]2nc3ncc(Br)cc3c2)ccc1F)OCC(Cl)(Cl)Cl Chemical compound O=C(Nc(cc1-[n]2nc3ncc(Br)cc3c2)ccc1F)OCC(Cl)(Cl)Cl LIZNKHLUXKNNMO-UHFFFAOYSA-N 0.000 description 1
- KKEPYKPRGXAHNQ-UHFFFAOYSA-N OB(c1cc2c[n](-c(cc(cc3)N/C(/N(C4)CC4F)=[O]/C4CC4)c3F)nc2nc1)O Chemical compound OB(c1cc2c[n](-c(cc(cc3)N/C(/N(C4)CC4F)=[O]/C4CC4)c3F)nc2nc1)O KKEPYKPRGXAHNQ-UHFFFAOYSA-N 0.000 description 1
- KDGYCZQDBJRIHC-UHFFFAOYSA-N OB(c1cc2c[n](-c(cc(cc3)NC(N(C4)CC4F)=O)c3F)nc2nc1)O Chemical compound OB(c1cc2c[n](-c(cc(cc3)NC(N(C4)CC4F)=O)c3F)nc2nc1)O KDGYCZQDBJRIHC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762513211P | 2017-05-31 | 2017-05-31 | |
| US62/513,211 | 2017-05-31 | ||
| US201762581919P | 2017-11-06 | 2017-11-06 | |
| US62/581,919 | 2017-11-06 | ||
| PCT/IB2018/053818 WO2018220531A1 (en) | 2017-05-31 | 2018-05-29 | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2018276190A1 AU2018276190A1 (en) | 2019-11-07 |
| AU2018276190B2 true AU2018276190B2 (en) | 2020-05-14 |
Family
ID=62749123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018276190A Ceased AU2018276190B2 (en) | 2017-05-31 | 2018-05-29 | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US11384078B2 (https=) |
| EP (1) | EP3630771B1 (https=) |
| JP (1) | JP7187490B2 (https=) |
| KR (1) | KR20200010275A (https=) |
| CN (1) | CN110678468B (https=) |
| AR (1) | AR111826A1 (https=) |
| AU (1) | AU2018276190B2 (https=) |
| BR (1) | BR112019024804A2 (https=) |
| CA (1) | CA3060990A1 (https=) |
| CL (1) | CL2019003467A1 (https=) |
| CO (1) | CO2019013254A2 (https=) |
| CR (1) | CR20190545A (https=) |
| CU (1) | CU24543B1 (https=) |
| DO (1) | DOP2019000299A (https=) |
| EC (1) | ECSP19084722A (https=) |
| ES (1) | ES2927207T3 (https=) |
| IL (1) | IL270927B (https=) |
| JO (1) | JOP20190278A1 (https=) |
| MA (1) | MA50495A (https=) |
| MX (1) | MX389106B (https=) |
| PE (1) | PE20201148A1 (https=) |
| PH (1) | PH12019502652A1 (https=) |
| RU (1) | RU2738647C1 (https=) |
| TW (1) | TW201902894A (https=) |
| UY (1) | UY37745A (https=) |
| WO (1) | WO2018220531A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190278A1 (ar) * | 2017-05-31 | 2019-11-28 | Novartis Ag | مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية |
| EP4136066A1 (en) * | 2020-04-17 | 2023-02-22 | DSM IP Assets B.V. | A process for preparation of substituted enamine compounds |
| WO2021259163A1 (zh) * | 2020-06-23 | 2021-12-30 | 上海美悦生物科技发展有限公司 | 一种稠和吡唑类化合物的制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016193111A1 (en) * | 2015-05-29 | 2016-12-08 | Glaxosmithkline Intellectual Property Development Limited | Imidazo[1,2-b][1,2,4]triazine derivatives as antiparasitic agents |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10053275A1 (de) * | 2000-10-27 | 2002-05-02 | Dresden Arzneimittel | Neue 7-Azaindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung |
| KR101312736B1 (ko) | 2003-02-27 | 2013-09-27 | 팔라우 파르마 에스에이 | 피라졸로피리딘 유도체 |
| TW201238487A (en) | 2011-02-25 | 2012-10-01 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
| WO2013067302A1 (en) * | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
| WO2013106254A1 (en) * | 2012-01-11 | 2013-07-18 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
| CN105164124B (zh) | 2012-11-19 | 2017-03-15 | 诺华股份有限公司 | 用于治疗寄生虫疾病的化合物和组合物 |
| US9186361B2 (en) * | 2013-03-15 | 2015-11-17 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
| UY35400A (es) * | 2013-03-15 | 2014-10-31 | Novartis Ag | Compuestos y composiciones para el tratamiento de enfermedades parasitarias |
| TWI674263B (zh) * | 2013-12-19 | 2019-10-11 | 瑞士商諾華公司 | 用於治療寄生蟲疾病之化合物及組合物 |
| EP3227288B1 (de) | 2014-12-02 | 2018-08-29 | Bayer CropScience AG | Bicyclische verbindungen als schädlingsbekämpfungsmittel |
| CN112608300B (zh) | 2015-03-11 | 2024-04-26 | Fmc公司 | 杂环取代的二环唑杀有害生物剂 |
| EP3331885B1 (en) * | 2015-08-07 | 2020-12-23 | GlaxoSmithKline Intellectual Property Development Limited | Compounds |
| CN114984003B (zh) * | 2016-05-03 | 2024-08-27 | 拜耳制药股份公司 | 芳族磺酰胺衍生物 |
| JOP20190278A1 (ar) * | 2017-05-31 | 2019-11-28 | Novartis Ag | مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية |
-
2017
- 2017-06-16 JO JOP/2019/0278A patent/JOP20190278A1/ar unknown
-
2018
- 2018-05-23 UY UY0001037745A patent/UY37745A/es not_active Application Discontinuation
- 2018-05-24 AR ARP180101377A patent/AR111826A1/es unknown
- 2018-05-29 CR CR20190545A patent/CR20190545A/es unknown
- 2018-05-29 CN CN201880034658.0A patent/CN110678468B/zh active Active
- 2018-05-29 BR BR112019024804A patent/BR112019024804A2/pt not_active Application Discontinuation
- 2018-05-29 WO PCT/IB2018/053818 patent/WO2018220531A1/en not_active Ceased
- 2018-05-29 MA MA050495A patent/MA50495A/fr unknown
- 2018-05-29 CU CU2019000095A patent/CU24543B1/es unknown
- 2018-05-29 US US16/615,749 patent/US11384078B2/en active Active
- 2018-05-29 MX MX2019014321A patent/MX389106B/es unknown
- 2018-05-29 ES ES18734297T patent/ES2927207T3/es active Active
- 2018-05-29 CA CA3060990A patent/CA3060990A1/en active Pending
- 2018-05-29 AU AU2018276190A patent/AU2018276190B2/en not_active Ceased
- 2018-05-29 EP EP18734297.7A patent/EP3630771B1/en active Active
- 2018-05-29 KR KR1020197034689A patent/KR20200010275A/ko not_active Withdrawn
- 2018-05-29 TW TW107118305A patent/TW201902894A/zh unknown
- 2018-05-29 RU RU2019138326A patent/RU2738647C1/ru active
- 2018-05-29 JP JP2019565535A patent/JP7187490B2/ja active Active
- 2018-05-29 PE PE2019002477A patent/PE20201148A1/es unknown
-
2019
- 2019-11-25 PH PH12019502652A patent/PH12019502652A1/en unknown
- 2019-11-26 CO CONC2019/0013254A patent/CO2019013254A2/es unknown
- 2019-11-26 IL IL270927A patent/IL270927B/en unknown
- 2019-11-27 DO DO2019000299A patent/DOP2019000299A/es unknown
- 2019-11-27 CL CL2019003467A patent/CL2019003467A1/es unknown
- 2019-11-27 EC ECSENADI201984722A patent/ECSP19084722A/es unknown
-
2022
- 2022-05-13 US US17/744,432 patent/US20220324863A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016193111A1 (en) * | 2015-05-29 | 2016-12-08 | Glaxosmithkline Intellectual Property Development Limited | Imidazo[1,2-b][1,2,4]triazine derivatives as antiparasitic agents |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016371014B2 (en) | Polycyclic TLR7/8 antagonists and use thereof in the treatment of immune disorders | |
| EP4626555A1 (en) | Glutarimide-containing pan-kras-mutant degrader compounds and uses thereof | |
| JP7774709B2 (ja) | インターロイキン－１受容体関連キナーゼの二官能性分解剤及びその治療的使用 | |
| BR112021002090A2 (pt) | derivado azabicíclico opticamente ativo | |
| EP2970324A1 (en) | Compounds and compositions for the treatment of parasitic diseases | |
| AU2016293441A1 (en) | Indazole and azaindazole compounds as IRAK-4 inhibitors | |
| CN103764653A (zh) | 作为c-Kit激酶抑制剂的化合物和组合物 | |
| US20220324863A1 (en) | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases | |
| TW201211053A (en) | Spiro compound and drug for activating adiponectin receptor | |
| KR102359707B1 (ko) | 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도 | |
| US20200352931A1 (en) | Oxalamides as modulators of indoleamine 2,3-dioxygenase | |
| WO2023239629A1 (en) | Compounds and pharmaceutical compositions that degrade cdk2 | |
| WO2024044570A1 (en) | Compounds and methods for modulating her2 | |
| JP2019520397A (ja) | チロシンキナーゼ阻害剤 | |
| JP2025530793A (ja) | Ｅｇｆｒ阻害剤及びその使用 | |
| CN115232109A (zh) | Pd-1/pd-l1类小分子抑制剂及其在药物中的应用 | |
| KR20220146348A (ko) | 아데노신 A2a 수용체 길항제로서의 화합물 및 이를 포함하는 약학적 조성물 | |
| EA039324B1 (ru) | 5,6–конденсированные бициклические соединения и композиции для лечения паразитарных заболеваний | |
| RU2860767C2 (ru) | Ингибиторы nek7 | |
| WO2026007740A1 (zh) | 螺环化合物、其制备方法及用途 | |
| JP2026502170A (ja) | リガンド標的ｉｒａｋ３分解剤としての置換イミダゾ系化合物 | |
| KR20260053336A (ko) | Erk의 활성 조절을 위한 화합물 및 조성물 | |
| WO2024227026A1 (en) | Heterocyclic compounds as parp1 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |